Thinking About Medical Device Development Strategy in a Time of COVID-19 [Virtual]

Join Faegre Drinker as they explore the importance of reimbursement strategy for emerging medical device companies, including measures these companies can take ahead of FDA approval to promote a smooth reimbursement process and the ins and outs of Medicare reimbursement for medical device clinical trials. In addition, they will provide best practices for planning and executing clinical trials during COVID-19.

Presenters

• Ilisa Halpern Paul, President, District Policy Group, Faegre Drinker
• Amy Judge-Prein, Partner, Faegre Drinker
• Reed Abrahamson, Associate, Faegre Drinker

Register here.

Following this session, Faegre Drinker will be hosting virtual office hours/Q&A sessions.

• Sign up for office hours / Q&A with Ilisa Halpern Paul here.
• Sign up for office hours / Q&A with Amy Judge-Prein here.
• Sign up for office hours / Q&A with Reed Abrahamson here.

This question-and-answer discussion is for informational purposes only.  The material contained herein is general and is not intended to be legal advice.  It should not be relied upon or used without consulting a lawyer to consider your specific circumstances, possible changes to applicable laws, rules and regulations and other legal issues.  Receipt of this material does not establish an attorney-client relationship.